关于用于癌症治疗的EZH2抑制剂和降解剂的最新进展
在PubMed上查看摘要
概括
此摘要是机器生成的。通过阻断基因沉默,增强性同源2 (EZH2) 抑制剂对癌症治疗至关重要. 像双重抑制剂和降解剂这样的新策略旨在提高疗效并克服耐药性.
科学领域
- 表观遗传学
- 癌症生物学
- 药理学
背景情况
- 在表观遗传调节中,增强性同源2 (EZH2) 是关键,通过基因甲基化控制基因表达.
- EZH2失调与各种癌症有关,导致瘤发生和瘤进展.
- 针对EZH2是一种有前途的癌症治疗策略.
研究的目的
- 审查自2020年以来开发的EZH2向疗法.
- 讨论EZH2抑制剂和降解剂的进展.
- 探索未来优化EZH2向癌症治疗的方向.
主要方法
- 对EZH2向治疗的科学文献的审查.
- 对已批准的药物和临床试验数据的分析.
- 探索下一代治疗策略.
主要成果
- 在开发EZH2抑制剂和降解剂方面取得显著进展.
- 有几种针对EZH2的药物已获得批准或正在临床试验中.
- 下一代策略显示了提高疗效和抗药性管理的潜力.
结论
- 在癌症治疗中,EZH2抑制剂是一个至关重要的方法.
- 目前正在进行的研究重点是先进的抑制剂,降解剂和组合疗法.
- 未来的方向旨在最大限度地提高治疗效益并克服治疗耐药性.
相关概念视频
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

